Salud financiera de hoja de balance de Biosynex

Salud financiera controles de criterios 2/6

Biosynex tiene un patrimonio de los accionistas total de €142.5M y una deuda total de €68.0M, lo que sitúa su ratio deuda-patrimonio en 47.7%. Sus activos y pasivos totales son €272.2M y €129.7M respectivamente.

Información clave

53.1%

Ratio deuda-patrimonio

€65.96m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€26.16m
Patrimonio	€124.32m
Total pasivo	€117.41m
Activos totales	€241.73m

Actualizaciones recientes sobre salud financiera

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Jun 23

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Dec 19

Recent updates

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€125.8M) de ALBIO superan a sus pasivos a corto plazo (€95.3M).

Pasivo a largo plazo: Los activos a corto plazo (€91.4M) de ALBIO no cubren sus pasivos a largo plazo (€92.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (15.9%) de ALBIO se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de ALBIO ha crecido de 20.1% a 47.7% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de ALBIO es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de ALBIO sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Biosynex

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Recent updates

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investor sentiment deteriorates as stock falls 22%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Investor sentiment deteriorated over the past week

New 90-day high: €20.60

Investor sentiment improved over the past week

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €19.90

First half earnings released

New 90-day high: €13.50

New 90-day high: €12.50

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera